AtriCure
Valuation each multiple against its own 5-year range
Vs. peers Medical Instruments & Supplies
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| AtriCure (ATRC) | 2.82B | 178.68 | 5.29 | 0.00% |
| Intuitive Surgical (ISRG) | 138.33B | 48.25 | 8.65 | 0.00% |
| Becton Dickinson & Co (BDX) | 57.96B | 52.02 | 2.35 | 1.97% |
| Alcon (ALC) | 35.92B | 54.24 | 1.64 | 0.48% |
| ResMed (RMD) | 33.14B | 21.46 | 5.57 | 1.04% |
| Medline (MDLN) | 32.55B | 57.52 | 2.76 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 3.9% below Morningstar's fair value estimate.
Fair value
AtriCure Inc earns a 3-star quantitative star rating, illustrating our stance that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a minor 1% discount to our quantitative fair value estimate of $57.52 per share; however, caution is warranted due to this estimate's high uncertainty rating.
The firm's solid growth bolsters our estimated fair value. Consistent revenue and earnings growth indicates a company's potential for increased market share and profitability. Reflecting the firm's growth is its EBITDA per share growth, which ranks in the top 30% globally. This suggests rapid margin expansion is underway, or new markets are being tapped, which contributes to our view that shares are cheap.
On a different note, the company's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's sales yield of 20.5%, for example, falls in the bottom 20% compared with global peers. This company's inability to generate significant sales growth without meaningful capital investment is a challenge, which, despite our favorable price/fair value ratio, is a negative attribute.
Economic moat
With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.
By Quantitative Equity Report
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
AtriCure discussion 0 comments